The effect of the glycine/NMDA receptor antagonist, (+)-HA966, on morphine dependence in neuropathic rats

Neuropharmacology

Volumn 39, Issue 9, 2000, Pages 1589-1595

  Christensen, Dennis ^a   Guilbaud, Gisèle ^a   Kayser, Valérie ^a  

^a INSERM   (France)

Author keywords

(+) HA966; Glycine site; Morphine dependence; Morphine withdrawal; Neuropathic pain; NMDA receptor antagonist

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; MALE; MORPHINE ADDICTION; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCIATIC NEUROPATHY; SODIUM CHLORIDE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0034085966     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00236-1     Document Type: Article

References (43)

1. Aley K.O., Levine J.D. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. Journal of Neuroscience. 17:1997;8018-8023.
2. Aley K.O., Levine J.D. Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. Journal of Neuroscience. 17:1997;3907-3912.
3. Attal N., Jazat F., Kayser V., Guilbaud G. Further evidence for a 'pain-related' behaviour in a model of unilateral peripheral mononeuropathy. Pain. 41:1990;235-251.
4. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces abnormal pain sensation like those seen in man. Pain. 33:1988;87-107.
5. Berger P., Farrel K., Sharp F., Skolnick P. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex. Neuroscience Letters. 168:1994;147-150.
6. Bläsig J., Herz A., Reinhold K., Zieglgänsberger S. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia. 33:1973;19-38.
7. Bristow L.J., Hogg J.E., Hutson P.H. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology. 36:1997;241-250.
8. Catheline G., Kayser V., Idänpään-Heikkilä J.J., Guilbaud G. The antinociceptive activity of kappa- but not delta-opioid receptor agonists is maintained in morphine-tolerant neuropathic rats. European Journal of Pharmacology. 318:1996;273-281.
9. Chen J., Graham S., Moroni F., Simon R. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. The Journal of Pharmacology and Experimental Theraputics. 267:1993;937-941.
10. Chen L., Huang L.-Y. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu-opioid. Neuron. 7:1991;319-326.
11. Christensen D., Idänpään-Heikkilä J.J., Guilbaud G., Kayser V. The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA receptor antagonist, (+)-HA966 in a rat model of neuropathic pain. British Journal of Pharmacology. 125:1998;1641-1650.
12. Christensen D., Guilbaud G., Kayser V. Effect of the glycine/NMDA receptor antagonist (+)-HA966 on morphine dependence in mononeuropathic rats. World Congress on Pain Abstracts. 9:1999;536.
13. Christensen, D., Guilbaud, G., Kayser, V., in press. Complete prevention, but stimulus-dependent reversion of morphine tolerance by the glycine/NMDA receptor antagonist, (+)-HA966 in neuropathic rats. Anesthesiology.
14. Collingridge G.L., Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends in Pharmacological Sciences. 11:1990;290-296.
15. Ethical standards and guidelines for investigations of experimental pain in animals. Pain. 16:1983;109-110.
16. Dafters R., Odber J. Effects of the dose, interdose interval, and drug-signal parameters on morphine analgesic tolerance: implications for current theories of tolerance. Behavioral Neuroscience. 103:1989;1082-1090.
17. Dickenson A.H. NMDA receptor antagonists as analgesics. Fields H.L., Liebeskind J.C. Progress in Pain Research and Management. 1994;173-187 International Association for the Study of Pain (IASP), Seattle, WA.
18. Dunbar S., Yaksh T.L. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology. 84:1996;1177-1188. published erratum appears in Anesthesiology 1996, 85 (3), 695.
19. El-Kadi A.O., Sharif S.I. The influence of various experimental conditions on the expression of naloxone-induced withdrawal symptoms in mice. General Pharmacology. 25:1994;1505-1510.
20. Fundytus M.E., Coderre T.J. Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. British Journal of Pharmacology. 113:1994;1215-1220.
21. Gonzalez P., Cabello P., Germany A., Norris B., Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. European Journal of Pharmacology. 332:1997;257-262.
22. Honoré P., Chapman V., Jaroslava B., Besson J.-M. Concomitant administration of morphine and an N-methyl-D-aspartate receptor antagonist profoundly reduces inflammatory evoked spinal c-fos expression. Anesthesiology. 85:1996;150-160.
23. Idänpään-Heikkilä J.J., Guilbaud G., Kayser V. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. The Journal of Pharmacology and Experimental Theraputics. 282:1997;1366-1372.
24. Johnson S.M., Duggan A.W. Dependence in the absence of tolerance to morphine. European Journal of Pharmacology. 97:1984;305-308.
25. Kayser V., Idänpään-Heikkilä J.J., Christensen D., Guilbaud G. The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats. Life Science. 62:1998;947-952.
26. Kemp J.A., Leeson P.D. The glycine site of the NMDA receptor - five years on. Trends in Pharmacology. 14:1993;20-25.
27. Kosten T.A., DeCaprio J.L., Rosen M.I. The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Neuropsychopharmacology. 13:1995;323-333.
28. Makimura M., Sugimoto H., Shinomiya K., Kabasawa Y., Fukuda H. Inhibitory effect of the NMDA receptor antagonist, dizocilpine (MK-801), on the development of morphine dependence. The Journal of Toxicological Sciences. 21:1996;135-141.
29. Maldonado R., Negus S., Koob G.F. Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology. 31:1992;1231-1241.
30. Manning B.H., Mao J., Frenk H., Price D.D., Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 67:1996;79-88.
31. Mao J., Price D.D., Caruso F.S., Mayer D.J. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 67:1996;361-368.
32. Martin G., Nie Z., Siggins G.R. mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons. Journal of Neuroscience. 17:1997;11-22.
33. Medvedev I.O., Dravolina O.A., Bespalov A.Y. Effects of N-methyl-D-aspartate receptor antagonists on discriminative stimulus effects of naloxone in morphine-dependent rats using the Y-maze drug discrimination paradigm. The Journal of Pharmacology and Experimental Theraputics. 286:1998;1260-1268.
34. Neil A., Kayser V., Chen Y.L., Guilbaud G. Repeated low doses of morphine do not induce tolerance but increase the opioid antinociceptive effect in rats with a peripheral neuropathy. Brain Research. 522:1990;140-143.
35. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
36. Popik P., Mamczarz J., Fraczek M., Widla M., Hesselink M., Danysz W. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology. 37:1998;1033-1042.
37. Portenoy R.K., Dole V., Joseph H., Lowinson J., Rice C., Segal S., Richman B.L. Pain management and chemical dependency. Evolving perspectives. JAMA. 278:1997;592-593.
38. Rahman A.F., Takahashi M., Kaneto H. Morphine dependence with or without tolerance in formalin-treated mice: further evidence for the dissociation. Japanese Journal of Pharmacology. 66:1994;277-280.
39. Shoemaker W.J., Kosten T.A., Muly S.M. Ethanol attenuation of morphine dependence: comparison to dizocilpine. Psychopharmacology (Berlin). 134:1997;83-87.
40. Siegel S. Classical conditioning and opiate tolerance and withdrawal. Balfour D.K.J. Psychotropic Drugs of Abuse. 1990;59-85 Pergamon, New York.
41. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
42. Trujillo K.A., Akil H. Opiate tolerance and dependence: recent findings and synthesis. New Biology. 3:1991;915-923.
43. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. Drugs. 55:1998;1-4.